Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation.

Abstract

BACKGROUND Preemptive rituximab (R) treatment decreases the incidence of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disease, but the extent of immune deficiency related to R in patients who received allogeneic hematopoietic stem-cell transplantation is unclear. The aim of our study was to evaluate the incidence of late infections and immune reconstitution after preemptive R treatment of EBV infection. METHODS Seventy-eight patients receiving preemptive R between January 2005 and January 2010 were studied. Fifty-two of them could be matched with controls (not receiving R) according to administration of antithymoglobulin, stem-cell source and donor type, age and grade of acute graft-versus-host disease. RESULTS Among the 78 patients with EBV reactivation treated with R, the 36-month cumulative incidence of bacterial, viral, and fungal infections was 64%, 59%, and 23%, respectively. When compared with controls, bacterial infection incidence was significantly higher in R patients (55% vs. 35%), and a slower reconstitution of B cells was observed. R patients had modest but not significantly higher nonrelapse mortality (35% vs. 15%) than controls. CONCLUSION R has dramatically decreased risks of posttransplantation lymphoproliferative disease but is followed by a prolonged and profound B-cell deficiency associated with an excess risk of bacterial infection and higher mortality. R should be given with caution, and immunoglobulin replacement should be provided to limit these excess risks.

DOI: 10.1097/TP.0b013e3182664042
0501002014201520162017
Citations per Year

88 Citations

Semantic Scholar estimates that this publication has 88 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Petropoulou2012IncreasedIR, title={Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation.}, author={Anna D. Petropoulou and Raphael Porcher and R{\'e}gis Peffault de Latour and Ali{\'e}nor Xhaard and Daniel J. Weisdorf and Patricia Ribaud and Paula Rodriguez-Otero and F{\'e}lix Agbalika and Alexis Talbot and Antoine Toubert and H{\'e}l{\`e}ne Moins-Teisserenc and Maryvonnick Carmagnat and Gerard J Soci{\'e} and Marie Robin}, journal={Transplantation}, year={2012}, volume={94 8}, pages={879-83} }